Name | 19-hydroxy-4-androsten-3,17-dione |
Synonyms | 19-HYDROXYANDROSTENDIONE 19-HYDROXYANDROSTENEDIONE 4-ANDROSTEN-19-OL-3,17-DIONE 4-ANDROSTENE-3,17-DIONE-19-0L 4-ANDROSTENE-3,17-DIONE-19-OL 19-HYDROXY-4-ANDROSTEN-3,17-DIONE 19-hydroxy-4-androsten-3,17-dione 19-hydroxyandrost-4-ene-3,17-dione 19-HYDROXY-4-ANDROSTENE-3,17-DIONE Androst-4-ene-3,17-dione, 19-hydroxy- (8xi,10xi,13xi)-19-hydroxyandrost-4-ene-3,17-dione |
CAS | 510-64-5 |
EINECS | 208-116-5 |
InChI | InChI=1/C19H26O3/c1-18-8-7-16-14(15(18)4-5-17(18)22)3-2-12-10-13(21)6-9-19(12,16)11-20/h10,14-16,20H,2-9,11H2,1H3/t14-,15-,16-,18-,19+/m0/s1 |
Molecular Formula | C19H26O3 |
Molar Mass | 302.41 |
Density | 1.19±0.1 g/cm3(Predicted) |
Melting Point | 168-169°C(lit.) |
Boling Point | 485.4±45.0 °C(Predicted) |
Flash Point | 261.5°C |
Solubility | Chloroform (Slightly), Methanol (Slightly) |
Vapor Presure | 1.84E-11mmHg at 25°C |
Appearance | Solid |
Color | Off-White to Pale Yellow |
BRN | 2567249 |
pKa | 14.90±0.10(Predicted) |
Storage Condition | Sealed in dry,Store in freezer, under -20°C |
Refractive Index | 1.571 |
Physical and Chemical Properties | Crystals (acetone/hexane). Melting point 170-171 °c. [Α] D 182 ° (chloroform). |
Risk Codes | R36/37/38 - Irritating to eyes, respiratory system and skin. R63 - Possible risk of harm to the unborn child |
Safety Description | S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S27 - Take off immediately all contaminated clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37 - Wear suitable protective clothing and gloves. |
WGK Germany | 3 |
HS Code | 29372900 |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
use | intermediates of norethindrone and ethinylestradiol. |
Production method | Using acetic acid gestational dienolone (5, 16-pregnandiene-3 β-ol-20-one 3-acetate) as raw material, after hydroxylamine hydrochloride oxime, rearrangement (to obtain dehydroepiandrosterone acetate), hydrolysis (HCl), addition, epoxidation, hydrolysis (removal of 3-acetyl group), oxidation (3-hydroxyl group), elimination (removal of HCl), Reduction, ring opening and other steps. |